Burning Rock Biotech (BNR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BNR · Stock Price

USD 16.58+14.25 (+613.12%)

Market Cap: $177.2M

Historical price data

Market Cap: $177.2MPipeline: 1 drugFounded: 2014HQ: Guangzhou, China

Sector Ranking#98 in Diagnostics & Precision Medicine #106 in Oncology (General)

Overview

Burning Rock Biotech's mission is to 'Guard Life via Science' by becoming a new pillar in the international healthcare industry. The company has established itself as a leader in China's precision oncology diagnostics market, with a portfolio of CE-marked kits, a CLIA/CAP-certified lab, and a U.S. FDA Breakthrough Device designation. Its strategy is built on a dual business model of selling IVD products and providing LDT services, while strategically investing in R&D for early cancer detection and a nascent therapeutic pipeline to drive long-term growth.

Oncology

Technology Platform

A proprietary, high-throughput next-generation sequencing (NGS) platform optimized for clinical oncology, integrating specialized wet-lab protocols for tissue and liquid biopsy with advanced bioinformatics pipelines to detect a comprehensive range of genomic alterations.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Furmonertinib	Adenocarcinoma of Lung	Phase 1/2

Funding History

3

Total raised:$150M

IPOUndisclosedUndisclosedJun 15, 2020

Series B$100MGICJun 15, 2017

Series A$50MSequoia Capital ChinaJun 15, 2015

Opportunities

The global shift towards liquid biopsy for cancer monitoring and the nascent multi-cancer early detection market represent massive, long-term growth vectors.

Supportive Chinese healthcare policy and the company's initial regulatory successes in Europe and the U.S.

provide pathways for geographic expansion beyond its domestic base.

Risk Factors

The company faces intense competition, regulatory hurdles for novel test approvals and reimbursement, and execution risks associated with its strategic expansion into therapeutic drug development.

Geopolitical tensions and the capital-intensive nature of the biotech sector also pose significant challenges.

Competitive Landscape

Burning Rock competes with domestic Chinese diagnostics firms (e.g., Genecast, Berry Oncology) and global leaders like Guardant Health and Foundation Medicine. Its differentiation lies in a comprehensive tissue + liquid portfolio, cost-effective platform, and strong pharma partnership services for clinical trials.